Vaccines

Yvonne Perrie, Randip Kaur, Malou Henriksen-Lacey

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

Abstract

Vaccines continue to offer the key line of protection against a range of infectious diseases; however, the range of vaccines currently available is limited. One key consideration in the development of a vaccine is risk-versus-benefit, and in an environment of perceived low risk, the benefit of vaccination may not be recognised. To address this, there has been a move towards the use of subunit-based vaccines, which offer low side-effect profiles but are generally weakly immunogenic. This can be compensated for by the development of effective adjuvants. Nanotechnology offers key attributes in this field through the ability of nanoparticulates to incorporate and protect antigens from rapid degradation, combined with their potential to effectively deliver the antigens to appropriate cells within the immune system. These characteristics can be exploited in the development of new adjuvants. This chapter will outline the applications of nanosystems in vaccine formulations and consider the mechanisms of action behind a range of formulations.

LanguageEnglish
Title of host publicationFundamentals of pharmaceutical nanoscience
EditorsIjeoma F. Uchegbu, Andreas G. Schätzlein, Woei Ping Cheng, Aikaterini Lalatsa
Place of PublicationNew York (US)
PublisherSpringer
Pages465-491
Number of pages27
ISBN (Electronic)978-1-4614-9164-4
ISBN (Print)978-1-4614-9163-7
DOIs
Publication statusPublished - 1 Nov 2013

Fingerprint

Vaccines
Antigens
Subunit Vaccines
Nanotechnology
Communicable Diseases
Immune System
Vaccination

Cite this

Perrie, Y., Kaur, R., & Henriksen-Lacey, M. (2013). Vaccines. In I. F. Uchegbu, A. G. Schätzlein, W. P. Cheng, & A. Lalatsa (Eds.), Fundamentals of pharmaceutical nanoscience (pp. 465-491). New York (US): Springer. https://doi.org/10.1007/978-1-4614-9164-4_17
Perrie, Yvonne ; Kaur, Randip ; Henriksen-Lacey, Malou. / Vaccines. Fundamentals of pharmaceutical nanoscience. editor / Ijeoma F. Uchegbu ; Andreas G. Schätzlein ; Woei Ping Cheng ; Aikaterini Lalatsa. New York (US) : Springer, 2013. pp. 465-491
@inbook{4025e74d695a4504acfab6b729775617,
title = "Vaccines",
abstract = "Vaccines continue to offer the key line of protection against a range of infectious diseases; however, the range of vaccines currently available is limited. One key consideration in the development of a vaccine is risk-versus-benefit, and in an environment of perceived low risk, the benefit of vaccination may not be recognised. To address this, there has been a move towards the use of subunit-based vaccines, which offer low side-effect profiles but are generally weakly immunogenic. This can be compensated for by the development of effective adjuvants. Nanotechnology offers key attributes in this field through the ability of nanoparticulates to incorporate and protect antigens from rapid degradation, combined with their potential to effectively deliver the antigens to appropriate cells within the immune system. These characteristics can be exploited in the development of new adjuvants. This chapter will outline the applications of nanosystems in vaccine formulations and consider the mechanisms of action behind a range of formulations.",
author = "Yvonne Perrie and Randip Kaur and Malou Henriksen-Lacey",
year = "2013",
month = "11",
day = "1",
doi = "10.1007/978-1-4614-9164-4_17",
language = "English",
isbn = "978-1-4614-9163-7",
pages = "465--491",
editor = "Uchegbu, {Ijeoma F.} and Sch{\"a}tzlein, {Andreas G.} and Cheng, {Woei Ping} and Aikaterini Lalatsa",
booktitle = "Fundamentals of pharmaceutical nanoscience",
publisher = "Springer",
address = "Germany",

}

Perrie, Y, Kaur, R & Henriksen-Lacey, M 2013, Vaccines. in IF Uchegbu, AG Schätzlein, WP Cheng & A Lalatsa (eds), Fundamentals of pharmaceutical nanoscience. Springer, New York (US), pp. 465-491. https://doi.org/10.1007/978-1-4614-9164-4_17

Vaccines. / Perrie, Yvonne; Kaur, Randip; Henriksen-Lacey, Malou.

Fundamentals of pharmaceutical nanoscience. ed. / Ijeoma F. Uchegbu; Andreas G. Schätzlein; Woei Ping Cheng; Aikaterini Lalatsa. New York (US) : Springer, 2013. p. 465-491.

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

TY - CHAP

T1 - Vaccines

AU - Perrie, Yvonne

AU - Kaur, Randip

AU - Henriksen-Lacey, Malou

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Vaccines continue to offer the key line of protection against a range of infectious diseases; however, the range of vaccines currently available is limited. One key consideration in the development of a vaccine is risk-versus-benefit, and in an environment of perceived low risk, the benefit of vaccination may not be recognised. To address this, there has been a move towards the use of subunit-based vaccines, which offer low side-effect profiles but are generally weakly immunogenic. This can be compensated for by the development of effective adjuvants. Nanotechnology offers key attributes in this field through the ability of nanoparticulates to incorporate and protect antigens from rapid degradation, combined with their potential to effectively deliver the antigens to appropriate cells within the immune system. These characteristics can be exploited in the development of new adjuvants. This chapter will outline the applications of nanosystems in vaccine formulations and consider the mechanisms of action behind a range of formulations.

AB - Vaccines continue to offer the key line of protection against a range of infectious diseases; however, the range of vaccines currently available is limited. One key consideration in the development of a vaccine is risk-versus-benefit, and in an environment of perceived low risk, the benefit of vaccination may not be recognised. To address this, there has been a move towards the use of subunit-based vaccines, which offer low side-effect profiles but are generally weakly immunogenic. This can be compensated for by the development of effective adjuvants. Nanotechnology offers key attributes in this field through the ability of nanoparticulates to incorporate and protect antigens from rapid degradation, combined with their potential to effectively deliver the antigens to appropriate cells within the immune system. These characteristics can be exploited in the development of new adjuvants. This chapter will outline the applications of nanosystems in vaccine formulations and consider the mechanisms of action behind a range of formulations.

UR - http://www.scopus.com/inward/record.url?scp=84955657538&partnerID=8YFLogxK

UR - http://link.springer.com/chapter/10.1007%2F978-1-4614-9164-4_17

U2 - 10.1007/978-1-4614-9164-4_17

DO - 10.1007/978-1-4614-9164-4_17

M3 - Chapter (peer-reviewed)

SN - 978-1-4614-9163-7

SP - 465

EP - 491

BT - Fundamentals of pharmaceutical nanoscience

A2 - Uchegbu, Ijeoma F.

A2 - Schätzlein, Andreas G.

A2 - Cheng, Woei Ping

A2 - Lalatsa, Aikaterini

PB - Springer

CY - New York (US)

ER -

Perrie Y, Kaur R, Henriksen-Lacey M. Vaccines. In Uchegbu IF, Schätzlein AG, Cheng WP, Lalatsa A, editors, Fundamentals of pharmaceutical nanoscience. New York (US): Springer. 2013. p. 465-491 https://doi.org/10.1007/978-1-4614-9164-4_17